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Gamma-aminobutyric acid (GABA) is a non-proteinogenic amino acid and is the main
inhibitory neurotransmitter in the mammalian brain. GABA’s stress-reducing, and sleep
enhancing effects have been established. However, although several human clinical trials
have been conducted, results regarding the role of natural and/or biosynthetic oral GABA
intake on stress and sleep are mixed. We performed a systematic review to examine
whether natural and/or biosynthetic oral GABA intake has an effect on stress and sleep.
We systematically searched on PubMed database for studies published up to February
2020 following PRISMA guidelines. Only placebo-controlled human trials that assessed
stress, sleep, and related psychophysiological outcomes as a response to natural GABA
(i.e., GABA that is present naturally in foods) or biosynthetic GABA (i.e., GABA that is
produced via fermentation) intake were included. Fourteen studies met the criteria and
were included in the systematic review. Although more studies are needed before any
inferences can be made about the efficacy of oral GABA consumption on stress and
sleep, results show that there is limited evidence for stress and very limited evidence for
sleep benefits of oral GABA intake.
Keywords: gamma amino butyric acid (GABA), stress, sleep, nutrients, food supplements
INTRODUCTION
Gamma-aminobutyric acid (GABA) is a four-carbon non-proteinogenic amino acid that is present
in bacteria, plants, and vertebrates. Initially, it was discovered in plants (Steward et al., 1949), it
was then identified in the mammalian brain (Roberts and Frankel, 1950), and subsequently in
animals (Roberts and Eidelberg, 1960) and several other organisms—including bacteria and fungi
(Bouche et al., 2003). In vertebrates, it is generated by the irreversible α-decarboxylation reaction
of L-glutamic acid or its salts, catalyzed by glutamic acid decarboxylase enzyme (Satya Narayan
and Nair, 1990) and functions as an inhibitory neurotransmitter in the central nervous system
(CNS) (Roberts and Frankel, 1950; Petroff, 2002), It has also been found in several peripheral tissues
(Erdö, 1985). GABA is critical to the functioning of the CNS, where ∼60–75% of all synapses are
GABAergic (Schwartz, 1988).
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In addition to its role as a neurotransmitter, GABA also
exists naturally in various foods, such as tea, tomato, soybean,
germinated rice, and some fermented foods, and could be
obtained from a normal diet (Diana et al., 2014; Rashmi et al.,
2018). For example, white tea and adzuki beans contain 0.5
and 2.01 g/kg GABA, respectively (Zhao et al., 2011; Liao et al.,
2013). On the other hand, much higher concentrations of GABA
could be produced by lactic acid bacteria (LAB) fermentation
(Dhakal et al., 2012). For instance, by using Lactobacillus brevis
NCL912 strain, 103.5 g/l GABA could be produced (Li et al.,
2010). Recently, LAB GABA has gained significant attention and
has been widely used as a functional food ingredient in various
markets due to its potential health benefits associated with GABA
(Boonstra et al., 2015).
It is worth mentioning that GABA has long been thought
to be unable to cross the blood–brain barrier (BBB) (Kuriyama
and Sze, 1971; Roberts, 1974), which raises questions about
the mechanisms of action behind its health benefits. However,
there are various accounts regarding GABA’s BBB permeability.
While some researchers argue that only small amounts of GABA
cross the BBB (Knudsen et al., 1988; Bassett et al., 1990), with
the discovery of GABA-transporter systems in the brain (i.e.,
passing of solutes by transcytosis, carrier-mediated transport,
or simple diffusion of hydrophobic substances), others believe
that the substantial amounts of GABA could cross the BBB
(Takanaga et al., 2001; Al-Sarraf, 2002; Shyamaladevi et al., 2002).
Additionally, as GABA is also present in the enteric nervous
system, it has been considered that GABA may act on the
peripheral nervous system through the gut-brain axis (Cryan
and Dinan, 2012). Although there is some evidence showing that
biosynthetic GABA could reach the human brain as evidenced
by various EEG responses (Abdou et al., 2006; Yoto et al., 2012),
to date, there are no data showing GABA’s BBB permeability in
humans. Although it has been shown that the blood GABA levels
were elevated 30min after oral GABA intake (Yamatsu et al.,
2016), it’s not known if oral GABA intake would increase brain
GABA concentrations or not.
Given the ubiquitous role of GABA as an inhibitory
neurotransmitter, along with its widespread distribution, it is
unsurprising that it has been implicated in a large range
of behaviors (Olney, 1990). These include anxiety and stress
regulation, circadian rhythm and sleep regulation, memory
enhancement, mood, and even perception of pain (Diana
et al., 2014; Rashmi et al., 2018). Low levels of GABA or
impaired GABA functioning is associated with the etiology and
maintenance of acute and chronic stress (Jie et al., 2018), anxiety
disorders (Nemeroff, 2003) and sleep disturbances such as
insomnia (Gottesmann, 2002). Specifically, GABAergic neurons
and neurotransmitters regulate the brain circuits in (i) the
amygdala to modulate stress and anxiety responses both in the
normal and pathological conditions (Nuss, 2015), (ii) cortico-
medullary pathways to modulate both rapid eye movement
(REM) and Non-REM, particularly slow wave sleep (SWS)
sleep (Luppi et al., 2017), and (iii) the suprachiasmatic nuclei
(SCN) to modulate circadian rhythm (DeWoskin et al., 2015).
Also, allosteric sites on the GABAa receptors allow the level of
inhibition of neurons in the relevant brain regions to be regulated
with high accuracy, and these sites are the molecular targets of
both anxiolytic and hypnotic drugs (Nuss, 2015; Riemann et al.,
2015). Hence, the pharmacological treatment of anxiety disorders
and insomnia usually employs a benzodiazepine receptor agonist
that affects GABAergic transmission (Nemeroff, 2003; Riemann
et al., 2015) which act by increasing the binding of GABA to
GABAa receptors in order to enhance inhibitory signals to cell
groups regulating arousal. This results in reduced stress and
anxiety, decreased sleep latency, and increased sleep continuity
(Gottesmann, 2002; Nemeroff, 2003; Nuss, 2015).
Whilst a limited number of human trials with a wide
range of methods (in terms of the dose of GABA, duration
of the intervention, and measures used to assess stress and
sleep) have investigated the impact of non-pharmacological
approaches to reduce stress and improve various aspects of
sleep by employing natural and biosynthetic GABA intake, to
our knowledge, this area of research has not been reviewed
systematically. Despite the high methodological variability of the
studies included in the current review, the objective of this review
is to carry out a systematic review and assess the robustness of
scientific evidence supporting the beneficial effects of oral GABA
(natural or biosynthetic) intake on stress, sleep, and related
psychophysiological measures.
METHODS
Selection of Studies
Inclusion Criteria
The inclusion criteria were the following:
• Outcome measures: stress, anxiety, sleep and/or related
psychophysiological parameters
• Design: randomized controlled trials and quasi-
experimental trials
• Participants: Any age or gender, healthy or
unhealthy participants.
Exclusion Criteria
The exclusion criteria were the following:
• Product: Synthetic GABA (i.e., Pharmaceutical-
grade substances)
• Design: Case report, letter to editor, conference paper, thesis,
personal opinion, or commentary
• Animal studies, in vitro and ex vivo studies.
Data Sources and Search Strategy
We carried out an electronic literature search on PubMed to
identify relevant studies. The search was conducted until the
beginning of February 2020. The search strings used in search
were GABA AND (stress OR sleep) NOT (gabapentin OR
pregabalin). Articles were selected according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) diagram (Moher et al., 2015; Shamseer et al., 2015).
One reviewer (PH) independently selected papers according
to the aforementioned inclusion and exclusion criteria. The
following information was extracted from all publications:
• Publication details: authors, year, journal
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FIGURE 1 | PRISMA flowchart of the selection procedure.
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FIGURE 2 | Risk of bias across studies.
• Participant characteristics: number of participants recruited,
number of participants included in the study, number of
participants (intervention), number of participants (control),
number of participants (other intervention), health status,
gender, and age range
• Study design: design and blinding
• Intervention characteristics: intervention duration, washout
period, GABA format, GABA type (natural or biosynthetic),
GABA dose, other intervention types and doses
• Control characteristics: presence/absence of control/placebo,
control/placebo doses
• Outcome measures: stress and sleep questionnaires,
cortisol, chromogranin A (CgA), immunoglobulin A (IgA),
adrenocorticotropic hormone (ACTH), adiponectin, heart
rate and heart rate variability, blood pressure, EEG variables
• Remarks: notes on the factors that might affect
results/data quality.
Study quality was also assessed by using Cochrane
Collaboration’s tool for assessing risk of bias in randomized trials
(Higgins et al., 2011).
RESULTS
We identified 5,912 publications and screened them for eligibility
using inclusion and exclusion criteria. Initially, 3,989 animal
studies, then a further 10 in vitro human studies were excluded.
One thousand three hundred forty-six studies that did not
measure stress and sleep-related outcomes were excluded.
Finally, 554 studies which did not examine consumption of
natural or biosynthetic GABA were excluded. Fourteen studies
met all the inclusion criteria were included in this review
(Figure 1).
One reviewer (PH) evaluated the quality of the studies
included in this review by using Cochrane Collaboration’s tool
for assessing risk of bias in randomized trials (Higgins et al.,
2011; Figure 2). The majority of the studies were categorized
as having an unclear risk of selection bias, because only one of
them reported the method used for random sequence generation
and allocation concealment. Performance bias, detection bias,
and attrition were observed as having low risk as most of the
studies were double-blind and reported all of the outcomes. Risk
for reporting bias was unclear as we were not sure if researchers
analyzed and reported all of the outcomes that could be extracted
from their selected methodologies. Finally, there was an unclear
bias for potential conflict of interest as one or more than one
authors of 11 studies were employed by an industrial company
at the time of publication.
Summaries of all the studies are presented in Table 1
(Methods) and Table 2 (Outcomes).
The Effect of GABA Consumption on Stress
Two experimental studies examined the effect of consuming
GABA-enriched natural products (such as tea and rice) on stress.
Although the majority of participant groups were reported to be
healthy, the dose of GABA, duration of the intervention, and
measures used to assess stress varied considerably.
A recent study by Hinton et al. (2019) investigating the acute
effects of GABA Oolong consumption on stress demonstrated
that in both (low and high) stress groups, both GABAOolong tea
(2.01mg GABA/200ml tea) and standard Oolong tea (0.25mg
GABA/200ml tea) increased average RR interval (the time
between two consecutive R waves in the electrocardiogram).
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TABLE 1 | Summary of the studies–methodology.
References Participants
(N and
characteristics)
Intervention (I) vs. control
(C)
Duration of
intervention
Design Dependent measures Time measures taken
Hinton et al.
(2019)
30 (11 males, age
range: 18–30,
healthy)
I: 2.01 mg GABA in 200ml
GABA Oolong Tea
C: 0.25mg GABA in 200ml
Oolong Tea
Single dose Single-blind, controlled,
parallel
Immediate stress questionnaire,
HRV (TP, LF, HF, LF/HF, RR interval)
Pre-ingestion and 30min
post-ingestion
Yoshida et al.
(2015)
39 (19 males, age
range: 45–60,
healthy)
I: 16.8mg GABA in 150 g
GABA rice/day
C: 4.1mg GABA in 150 g
white rice/day
8 weeks Double-blind, controlled,
parallel
VAS for calmness, worry,
sleepiness, and feeling of
awakening, cortisol, ACTH,
adiponectin
Pre-intervention (Week 0)
and Weeks 4, 8, and 10
Okada et al.
(2000)
20 (females only, age
range: 38–52,
healthy—post-
menopausal)
I: 26.4mg GABA in rice−3
times a day
C: Not clear
8 weeks Double-blind, controlled,
crossover
Kupperman menopause index
items
Pre-intervention (Week 0)
and Weeks 4, 8, and 16
Fujibayashi et al.
(2008)
12 (males only, age
range: 21–23,
healthy)
I: 30mg GABA + cellulose
(capsule)
C: Cellulose (capsule)
Single dose Double-blind, controlled,
crossover
HRV (TP, HF, LF) Pre-ingestion, 30 and
60min post-ingestion
Yamatsu et al.
(2015)
19 (males only, age
range: 24–45,
healthy)
I: 20mg GABA + 280ml
coffee
I: 280ml coffee
C: 280ml water
Single dose* Double-blind, controlled,
crossover
CgA Pre-ingestion, 30 and
60min post-ingestion
Kanehira et al.
(2011)
30 (16 males, age
range: 24–43, healthy
with chronic fatigue)
I: 25mg GABA + 250ml
hypotonic beverage
I: 50mg GABA + 250ml
hypotonic beverage
C: 250ml
hypotonic beverage
Single dose* Single-blind, controlled,
crossover
POMS, cortisol, CgA Pre-ingestion, at the
midpoint of the task
(15min post-ingestion),
and after the completion
of the task (35min
post-ingestion)
Nakamura et al.
(2009)
Experiment 1
12 (males only, age
range: 30–41,
healthy)
Experiment 2
12 (males only, mean
age: 31–42, healthy)
Experiment 1
I: 28mg GABA in 10 g
chocolate
C: 20 g chocolate
Experiment 2
I: 28mg GABA in 10 g
chocolate
C: 20 g chocolate
Experiment 1
Single dose*
Experiment 2
Single dose*
Experiment 1
Double-blind, controlled,
crossover
Experiment 2
Double-blind,
controlled, crossover
Experiment 1
HRV (HF, LF, HFnu, LF/HF)
Experiment 2
CgA
Pre-ingestion, at the
midpoint of the task
(30min post-ingestion),
after the completion of the
task (50min
post-ingestion)
Okita et al.
(2009)
7 (males only, age
range: 21–24,
healthy)
I: 31.8mg GABA in a
vegetable tablet
C: Placebo tablet with
Dextrin + Potato starch
+ Gardenia
Single dose Double-blind, controlled,
crossover
HR, HRV (LF, HF, LF/HF), BP (SBP,
DBP, MBP)
30 min-pre ingestion, 20,
40, and 60min
post-ingestion
(Continued)
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TABLE 1 | Continued
References Participants (N and
characteristics)
Intervention (I) vs. control
(C)
Duration of
intervention
Design Dependent measures Time measures taken
Yamatsu et al.
(2016)
10 (6 males, age
range: 24–57, poor
sleepers: PSQI >6)
I: 100mg GABA + 4.7mg
Glutamic acid, 2.3mg other
amino acids, 3.4mg
minerals and 1.6mg water
(112mg)—capsule
C: 112mg dextrin
1 week Single-blind, controlled,
crossover
PSQI Total, VAS for sleep
satisfaction, easiness to fall asleep,
and feelings upon awakening, EEG
for sleep latency, sleep efficiency,
Non-REM sleep latency, REM sleep
time, Non-REM sleep time, Light
Non-REM sleep time, Deep
Non-REM sleep time, Awakening
frequency, Delta wave
Pre-ingestion and
post-ingestion, exact
timelines are not clear
Yamatsu et al.
(2015)
16 (7 males, age
range: 27–45, poor
sleepers: PSQI >6)
I: 100mg GABA + 50mg
dextrin (capsule)
I: 100mg GABA + 50mg
AVLE (capsule)
I: 50mg AVLE + 100mg
dextrin (capsule)
C: 150mg dextrin (capsule)
1 week Single-blind, controlled,
crossover
PSQI Total, VAS for sleep
satisfaction, easiness to fall asleep,
and feelings upon awakening, EEG
for sleep latency, Non-REM sleep
latency, REM sleep time, Non-REM
sleep time, Awakening frequency,
Delta wave
Pre-ingestion and
post-ingestion, exact
timelines are not clear
Yoto et al. (2012) 63 (28 males, age
range: 20–28,
healthy)
I: 100mg GABA (capsule)
C: 100mg dextrin (capsule)
Single dose* Single-blind, controlled,
crossover
POMS-tension/anxiety, VAS for
arousal and relaxation, EEG-alpha
and beta wave
Pre-ingestion, 10, 40, and
70min post-ingestion
Abdou et al.
(2006)
Experiment 1
13 (7 males, age
range: 21–35,
healthy)
Experiment 2
8 (5 males, age
range:
25–30, acrophobic)
Experiment 1
I: 100mg GABA + 200ml
water
I: 200mg theanine + 200ml
water
C: 200ml water
Experiment 2
I: 100mg GABA + 200ml
water
C: 200ml water
Experiment 1
Single dose
Experiment 2
Single dose*
Experiment 1
Controlled, crossover
Experiment 2
Controlled, parallel
Experiment 1
EEG for alpha and beta wave
Experiment 2
IgA
Experiment 1
Pre-ingestion, at the time
of ingestion, 30 and
60min post-ingestion
Experiment 2
Before crossing, at
middle, and at the end of
the bridge
Byun et al.
(2018)
40 (10 males, age
range: 30–64, poor
sleepers: PSQI >5
and ISI >8)
I: 300mg GABA +
maltodextrin (tablet)
C: Maltodextrin (tablet)
4 weeks Double-blind, controlled,
parallel
ISI, PSQI for total score, sleep
quality, sleep latency, total sleep
time, sleep efficiency, PSG for total
sleep time, N1, N2, N3, REM,
WASO, Arousal Index, AHI, RDI,
REM sleep latency, sleep latency,
sleep efficiency
Pre-intervention and at the
end of Week 4
Yamatsu et al.
(2013)
38 (14 males, age
range: 71–92,
healthy)
I: 100mg GABA in 6.8 g
chocolate
C: Dextrin in 6.8 g chocolate
4 weeks Double-blind, controlled,
parallel
Cortisol, OSA sleep inventory Pre-ingestion, 30 and
60min after ingestion
*Utilized a stress task; HRV, heart rate variability; TP, total power; LF, low frequency power; HF, high frequency power; LF/HF, low frequency/high frequency ratio, HFnu: normalized high frequency power; VAS, visual analog scale;
ACTH, adrenocorticotropic hormone; CgA, chromogranin A; POMS, profile of mood states; HR, heart rate; BP, blood pressure; PSQI, Pittsburgh sleep quality index; EEG, electroencephalography; REM, rapid eye movement; IgA,
immunoglobulin A; ISI, insomnia severity index; PSG, polysomnography; WASO, wake after sleep onset; AHI, apnoea-hypopnea index; RDI, respiratory distress index; OSA, Oguri-Shirakawa-Azumi.
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TABLE 2 | Summary of the studies—outcomes.
References Stress effects Sleep effects
Hinton et al. (2019) - In both stress groups (low and high) both teas (regular oolong
and GABA oolong) tea increased average RR intervals. However,
GABA oolong (vs. regular oolong) had a greater significant
influence—bigger increase on HRV (a change in in the RR interval)
in high (vs. low) stressed individuals. - Immediate stress
questionnaire, TP, LF, HF, LF/HF—not significant
- Not measured
Yoshida et al. (2015) - Improved calmness and worry scores in GABA (vs. control)
group at the 4th week of treatment - Trends for reduced cortisol
and increased adiponectin in GABA (vs. control) group at the 8th
(final) week of treatment - ACTH: not significant
- A trend for improved feelings of awakening in GABA (vs. control)
group at the 4th and 10th weeks of treatment
- VAS sleepiness score- not significant
Okada et al. (2000) - Not measured - Improved rate for sleep disturbance scores (derived from
Kupperman Index) in GABA (vs. control) condition after 4 weeks of
use−68% of improvement
Fujibayashi et al. (2008) - Increased TP in GABA condition 30 and 60min after ingestion
(vs. baseline) - Increased HF in GABA condition 30min after
ingestion (vs. baseline) - TP and HF: no difference between GABA
and control conditions - LF: not significant
- Not measured
Yamatsu et al. (2015) - Reduced CgA in GABA coffee (vs. water and coffee) condition
30min after administration
- Not measured
Kanehira et al. (2011) - Lower cortisol and CgA after ingestion of both 25 and 50mg
GABA (vs. control) only in chronic fatigue group - Tension/anxiety
score—not significant
- Not measured
Nakamura et al. (2009) Experiment 1
- Lower LF/HF and higher HF power values in GABA (vs. control)
condition 6.5–9.5min after the task (= 36.5–39.5min
after ingestion) - Higher HF power values in GABA (vs. control)
condition 12–15min after the task (= 42–45min after ingestion)
Experiment 2
- Higher CgA values (due to stress task) in placebo condition 30
and 50min (vs. baseline) after ingestion. Not observed in
GABA condition
- Not measured
Okita et al. (2009) - Increased LF/HF ratio and HR in control condition 20 and 40min
after intake but this increase was not observed for GABA condition
- Stroke volume, cardiac output, HF and LF power, SBP, DBP,
MBP—not significant
- Not measured
Yamatsu et al. (2016) - Not measured - Improved feelings upon awakening score, reduced sleep latency
and increased total Non-REM (N1, N2, N3) sleep time in GABA (vs.
control) condition after treatment
- Trends for improved PSQI, sleep satisfaction, and ease of falling
asleep scores and increased light Non-REM (N1, N2) sleep time and
sleep efficiency in GABA (vs. control) condition after treatment
- Deep Non-REM (N3-SWS), sleep latency and time, REM sleep
time, awakening frequency, and delta wave power—not significant
Yamatsu et al. (2015) - Not measured - A trend for reduced sleep latency in GABA (vs. control) condition
after treatment
- PSQI total, sleep satisfaction, feeling of awakening, ease of
falling asleep, deep Non-REM (N3-SWS) sleep latency, REM sleep
time, Non-REM sleep time, awakening frequency and delta wave
power—not significant
Yoto et al. (2012) - Alpha and beta waves decreased from 20 to 60min after intake
(due to stress task) but 30min after GABA intake, this decrease
diminished in GABA (vs. control) condition - Tension/anxiety,
arousal, and relaxation scores—not significant
- Not measured
Abdou et al. (2006) Experiment 1
- Increased changes for alpha waves (%) in GABA (vs.
placebo) condition - Increased changes for alpha/beta ratio (%) in
GABA (vs. placebo and theanine) condition - A trend for reduced
changes for beta waves (%) in GABA vs. placebo condition
Experiment 2
Decreased IgA in control (vs. GABA) group at the middle and end
of the bridge
- Not measured
(Continued)
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TABLE 2 | Continued
References Stress effects Sleep effects
Byun et al. (2018) - Not measured - Reduced sleep latency in GABA (vs. control) group after treatment
- Decreased ISI, PSQI total, PSQI-sleep quality and PSQI-total
sleep time scores in GABA group (pre vs. post-treatment)—but no
between group differences
- PSQI-sleep latency, PSQI-sleep efficiency, N1(%), N2(%), N3(%),
REM (%), WASO(min), REM-sleep latency, arousal index, AHI,
RDI—not significant
Yamatsu et al. (2013) - Increased cortisol in placebo group after 2 and 4 weeks but not
in GABA group
- Improved onset and maintenance of sleep, drowsiness in the
morning, and recovering from fatigue scores in GABA group after
4 weeks but no placebo vs. GABA group analyses done
HRV, heart rate variability; ACTH, adrenocorticotropic hormone; HF, high frequency; LF, low frequency; CgA, chromogranin A; SBP, systolic blood pressure; DBP, diastolic blood pressure;
MBP, mean blood pressure; REM, rapid eye movement; PSQI, Pittsburgh sleep quality index; ISI, insomnia severity index; N1, Stage 1 Non-REM sleep; N2, Stage 2 Non-REM sleep;
N3-Stage 3 Non-REM sleep; WASO, wake after sleep onset; AHI, apnoea-hypopnea index; RDI, respiratory distress index.
However, GABA Oolong had a greater influence on heart rate
variability (HRV), eliciting a bigger change in RR interval in high
compared to low stressed individuals. The effects of GABA on
other HRV parameters and subjective stress were not significant.
Another study by Yoshida et al. (2015) showed that 8 weeks
consumption of GABA rice (16.8mg GABA in 150 g GABA
rice/day) improved subjective calmness andworry scoresmidway
through the study at the 4th week of the treatment compared
to white rice (4.1mg GABA in 150 g GABA rice/day), however,
these effects were not maintained. They also reported trends for
reduced blood cortisol and increased adiponectin levels in GABA
rice (vs. white rice) condition at the 8th week of the treatment.
However, they did not observe any effects on adrenocorticotropic
hormone (ACTH) at any stage of the intervention.
All of the eight experimental studies investigated the effects of
(i) single (Abdou et al., 2006; Fujibayashi et al., 2008; Nakamura
et al., 2009; Okita et al., 2009; Kanehira et al., 2011; Yoto et al.,
2012; Yamastsu et al., 2015) and (ii) repeated (Yamatsu et al.,
2013) biosynthetic GABA consumption on stress—mainly on
psychophysiological parameters, with doses ranging between 20-
−100mg and participant numbers between 7–63.
Fujibayashi et al. (2008) showed that 30mg GABA ingestion
increased (i) total power (TP) 30 and 60min after ingestion
compared to baseline and (ii) high frequency power (HF) 30min
after ingestion compared to baseline, however they failed to
show between group differences and differences in other HRV
parameters. In contrast, Okita et al. (2009) reported that the
placebo tablet increased the LF/HF ratio and heart rate (HR) 20
and 40min after consumption. This increase was not observed in
the GABA condition (31.8mg GABA), but they did find effects
of GABA consumption on other parameters including stroke
volume, cardiac output, HF and LF power, systolic blood pressure
(SBP), diastolic blood pressure (DBP), and mean blood pressure
(MBP). Using electroencephalography (EEG), experiment 1 from
Abdou et al. (2006) showed that 100mg GABA in 200ml
water increased changes in (i) alpha waves (compared to water
condition) and (ii) alpha/beta ratio (compared to water and
theanine condition). They also reported a trend for reduced
changes for beta waves in GABA vs. water condition. The only
4 week-long interventional study utilizing biosynthetic GABA
observed an increase in cortisol levels in the placebo group after
2 and 4 weeks of GABA use, but GABA group did not show such
an increase (Yamatsu et al., 2013).
The other studies utilized various methodologies to induce
stress on participants. Yamastsu et al. (2015) utilized the
Uchida-Kraepelin Psychodiagnostic Test (UKT; Kuraishi, 2000),
an arithmetic task to induce stress, and demonstrated that
20mg GABA in coffee (compared to coffee only and water
conditions) reduced chromogranin A (CgA) levels 30min after
consumption. A similar study utilizing UKT and CgA levels
(Kanehira et al., 2011) showed that consumption of both 25
and 50mg GABA in a 250ml hypotonic beverage (compared
to hypotonic beverage only condition) lowered salivary CgA
and cortisol in individuals with chronic fatigue. However, the
subjective tension/anxiety score was not significant. Nakamura
et al. (2009) measured both CgA and HRV and found that
28mg GABA in 10 g chocolate, compared to 20 g chocolate alone,
decreased the LF/HF power 6.5–9.5min after the arithmetic task
(i.e., = 36.5–39.5min after ingestion) and increased the HF
power 12–15min after the arithmetic task (i.e.,= 42–45min after
ingestion). They also reported that the CgA values increased in
the chocolate only condition 30 and 50min (vs. baseline) after
ingestion, an effect not observed in GABA chocolate condition.
The electrophysiological study by Yoto et al. (2012) employed
EEG to demonstrate that the UKT decreased alpha and beta
band power, whereas 30min after a 100mg GABA capsule (vs.
placebo capsule) intake, this decrease had diminished. Although
participants failed to report a subjective increase in relaxation and
decrease in tension/anxiety and arousal scores. Unlike the studies
above, experiment 2 from Abdou et al. (2006) on the other hand,
utilized a real life stress task, where acrophobic participants were
asked to cross a suspended bridge. They discovered that control
groups immunoglobulin A (IgA) levels decreased at the middle
and end of the bridge, but 100mg GABA capsule groups IgA
levels did not show this pattern.
The Effect of GABA Consumption on Sleep
Two 8-week intervention studies examined the effect of
consuming GABA-enriched rice on sleep in healthy individuals.
Yoshida et al. (2015), studying healthy middle aged individuals
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with poor sleep, found a trend for improved feelings upon
awakening in GABA rice (16.8mg GABA in 150 g GABA
rice/day) (vs. white rice−4.1mg GABA in 150 g white rice/day)
group at the 4th week of intervention and after 2 weeks
of the intervention (i.e., at the 10th week). They did not
find an effect of GABA rice on VAS sleepiness score.
Conversely Okada et al. (2000) reported, in post-menopausal
women, that consumption of 26.4mg GABA rice 3 times
a day (compared to control rice) improved insomnia score
of Kupperman Menopause Index at the 4th week of the
treatment. Additionally, only one 4-week long study examined
the effect of biosynthetic GABA consumption on sleep in
healthy elderly participants. Using the OSA sleep inventory they
showed improvements in the onset and maintenance of sleep,
drowsiness in the morning, and recovering from fatigue scores
in the GABA group after 4 weeks of treatment, although they
did not find differences between GABA and placebo groups
(Yamatsu et al., 2013).
Three 1 to 3-week long intervention studies (albeit with
very low sample sizes), investigated the effects of biosynthetic
GABA consumption on sleep in individuals with poor sleep
quality (one with PSQI > 5 scorers, and two with PSQI >
6 scorers; PSQI: Pittsburgh Sleep Quality Index). In their first
1 week long intervention study, Yamatsu et al. (2016) showed
that the intake of 100mg GABA capsule (vs. control) improved
feelings upon awakening scores, objectively measured reduced
sleep latency, and increased total Non-REM (N1, N2, and
N3/SWS) sleep time after intervention. They also observed
trends for improved PSQI, sleep satisfaction, and ease of falling
asleep scores and increased light Non-REM sleep time and
sleep efficiency in GABA (vs. control) condition after treatment.
However, they did not find significant effects for deep Non-
REM (N3/SWS) sleep latency and time (i.e., duration), REM
sleep time, awakening frequency, or delta wave power. In
their other 1 week intervention study, Yamatsu et al. (2015),
studying middle aged sleepers who reported having poor sleep,
observed a trend for reduced sleep latency only in 100mg GABA
capsule (vs. control) condition. Results from PSQI total, sleep
satisfaction, feeling of awakening, ease of falling asleep scores
and Non-REM sleep latency, REM sleep time, Non-REM sleep
time, awakening frequency and delta wave power were not
significant for GABA only vs. other intervention (AVLE and
AVLE+GABA) and control groups. The most recent 4 week
long intervention study in this area by Byun et al. (2018),
studying middle aged sleepers who reported having poor sleep,
reported that 300mg GABA tablet (vs. control tablet) intake
reduced sleep latency after the intervention. They also found
that N2 sleep (%) and insomnia severity index (ISI) decreased,
as did PSQI total, PSQI-sleep quality, PSQI-sleep latency and
PSQI-total sleep time scores in GABA group (pre vs. post-
treatment), however, they failed to find GABA vs. placebo/group
differences. Additionally, there were no statistically significant
effects of PSQI-sleep efficiency scores, and total sleep time,
stage 1, and 3 Non-REM sleep (%), REM (%), wake after sleep
onset (WASO; min), REM-sleep latency, sleep efficacy, arousal
index, apnoea-hypopnea index (AHI), and respiratory distress
index (RDI).
DISCUSSION
Summary of the Main Results
This systematic review aimed to establish the current status
of knowledge regarding the effects of natural and biosynthetic
GABA consumption on stress and sleep. Overall, our review of
the literature showed that there was low to moderate evidence for
GABA’s stress (due to the fact that there are more studies with
positive results) and low evidence for GABA’s sleep benefits.
Methodologies of the studies included in this review varied
significantly but included both subjective and objective measures
of stress and sleep. The majority of the studies did not
find significant subjective improvements of stress scores after
consuming a single dose of either natural or biosynthetic forms
of GABA. Evidence for extended GABA use is mixed, Yoshida
et al. (2015) study which reported improved calmness and
worry scores in GABA (vs. control) group at the 4th week of
treatment, but not with GABA use beyond that. On the other
hand, only some of the subjective sleep scores including sleep
disturbance, feelings upon awakening, onset and maintenance
of sleep, drowsiness in the morning, and recovery from fatigue
scores improved only when there was a prolonged GABA use for
at least 1 week (Okada et al., 2000; Yamatsu et al., 2013, 2016).
Remaining studies showed either trends toward improvements
or insignificant subjective improvement of sleep. It may well be
the case that prolonged natural GABA use is required to elicit
subjective stress and sleep benefits.
Stress
Due to GABA’s BBB permeability issues, most of the studies
utilized autonomic nervous system (ANS)-related measures
(such as HRV, cortisol, and CgA) to examine the impact
of GABA consumption on stress. Abdou et al. (2006) and
Yoto et al. (2012) utilized EEG to evaluate the central action
of GABA. The studies using ANS-related measures showed
positive but rather conflicting results. Hinton et al. (2019)
reported increased RR intervals in the GABA condition that
reflects more stable ANS function through an increase in
vagal activity (indicative of reduced stress response) (Camm
et al., 1996). Similarly, although no treatment differences were
reported between GABA and control conditions, Fujibayashi
et al. (2008) showed an increased TP in GABA condition 30
and 60min after ingestion (vs. baseline) which is indicative of
ANS functionality and adaptability and reduced stress (Camm
et al., 1996). The same study reported increased HF in GABA
condition 30min after ingestion (vs. baseline) which is indicative
of increased PNS activity and reduced stress (Berntson et al.,
1997). Increased RR intervals, TP and HF suggests that GABA
exerts its effects by parasympathetic augmentation with no or
smaller sympathetic effects.
The remainder of the studies that utilized ANS-measures
showed the opposite activation pattern. LF/HF, a marker of SNS
activity and sympathovagal balance which increases under stress
conditions (Pagani et al., 1991) was either not increased (Okita
et al., 2009) or reduced in the GABA condition (Nakamura et al.,
2009). Similarly, CgA, a protein co-released with noradrenaline
in the SNS (Dimsdale et al., 1992), and cortisol, a glucocorticoid
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hormone that is released by the adrenal cortex via (i) release
of adrenocorticotropic hormone by regulation of hypothalamic–
pituitary–adrenal axis and (ii) the SNS innervation (Engeland
and Arnhold, 2005), were reduced in GABA vs. control
conditions (Nakamura et al., 2009; Kanehira et al., 2011;
Yamastsu et al., 2015), indicative of reduced stress levels. Also,
IgA, a glycoprotein that is regulated by the SNS (Carpenter et al.,
1998) that is lower in anxiety (Graham et al., 1988), was found
to be decreased in control but not in GABA conditions during a
stressful task (Abdou et al., 2006), suggesting a stress-protective
effect of GABA. According to these studies, GABA induced
relaxation by modulating the sympathetic nervous system.
Although there is no consensus regarding which division
of the autonomic nervous system is most affected by GABA
intake, there is limited evidence that GABA also crosses the
BBB and exerts biological effects on the CNS. Stress reduction
and relaxation are associated with enhanced alpha oscillations
(Nobre et al., 2008), reduced beta activity (Ray and Cole, 1985),
and increased alpha/beta ratio (Liang et al., 2019; Yi Wen
and Mohd Aris, 2020). In line with this, Abdou et al. (2006)
observed increased changes for alpha waves and alpha/beta
ratio in GABA (vs. placebo) condition, suggesting improved
relaxation. Similarly, Yoto et al. (2012) reported that both alpha
and beta waves decreased due to a stress task, but 30min after
GABA intake, this decrease diminished in GABA (vs. control)
condition, indicating a stress-protective effect of GABA. These
results suggest that, GABA passes the BBB either in small or full
amounts to exert biological effects on the CNS.
In summary, stress markers of both divisions of the ANS and
the CNS seem to be affected by oral GABA intake. However,
it is important to note that the efficacious doses for stress
reduction and/or stress-protective benefits range from 2.01 to
100mg, where the lower doses up to 30mg seem to affect
the autonomic markers of stress and a dose of 100mg seems
to affect the central markers of stress. Additionally, efficacious
doses for natural GABA seem to be lower than that of the
biosynthetic forms. Although natural GABA intake and stress
research is very limited, these results may also be attributable
to the other bioactive compounds found naturally in foods that
have stress reduction benefits such as l-theanine (Juneja et al.,
1999) and epigallocatechin gallate (EGCG) in tea (Scholey et al.,
2012). Further studies are warranted to examine (i) natural
and biosynthetic GABA bioavailability in humans following oral
intake in order to understand GABA’s mechanism of action for
each type of GABA, (ii) the minimum and optimum natural
and biosynthetic GABA doses required for stress benefits, and
(iii) the minimum and optimum natural and biosynthetic GABA
doses required to affect stress reduction/relaxation peripherally
and centrally.
Sleep
There is only very limited supportive evidence regarding the
role of oral GABA intake on objective sleep improvement. Byun
et al. (2018), whose participants were dosed 1 h before sleeping,
reported that 4 weeks use of GABA reduced sleep latency in
GABA (vs. control) group. Similarly, Yamatsu et al. (2016),
with dosing 30min before sleep, showed that 1 week GABA
intervention reduced sleep latency and increased total Non-
REM sleep time in GABA (vs. control) condition. However,
in a previous study with the same dosing regimen, Yamatsu
et al. (2015) only observed a trend toward reduced sleep latency
after 1 week of GABA consumption. All three studies failed
to show beneficial effects of GABA intake on other markers
of sleep such as sleep efficiency, REM sleep time, awakening
frequency etc. These findings suggest that prolonged GABA
intake (i.e., repeated dosing across days) may be beneficial
for naturally inducing sleep rather than maintaining sleep, as
evidence showed that GABA primarily affects sleep onset and
early stages of sleep that occur early at night (i.e., the first
Non-REM of the night), but not the stages of sleep that occur
later at night. This could be explained by the pharmacokinetic
profile of GABA, characterized by a rapid increase (30min
after oral administration) and then decrease (60min after oral
administration) in plasma concentrations. In other words, the
quick elevation in the blood GABA levels might explain as to
why it differentially affects early sleep markers. Additionally,
there is a bi-directional relationship between sleep and both
acute and chronic anxiety where sleep disturbance is observed
in individuals with anxiety (Soehner and Harvey, 2012) and
having a sleep disturbance may predict the development of an
anxiety disorder (Neckelmann et al., 2007). Specifically, increased
sleep onset latency has been observed in anxiety and related
disorders (Cox and Olatunji, 2016) and stress (Maskevich et al.,
2020). Therefore, early sleep stage-related benefits of GABA
consumption could be associated with GABA’s stress reduction
properties, rather than direct sleep inducing and/or maintaining
benefits per se. The lack of sleep maintenance-related benefits
of GABA might also be explained by (i) small and unequal
group sizes that mask real improvements, (ii) insufficient GABA
amounts that does not drive SWS and REM responses, and (iii)
not utilizing split-night PSG/EEG and masking the significant
changes that may only be evident in different parts of the night.
Repeated GABA intake across days may improve early sleep
parameters; however, it is important to note that doses required
to elicit sleep benefits (ranging between 100 and 300mg for
biosynthetic GABA) seem to be higher than that of stress benefits
(ranging between 20 and 100mg for biosynthetic and 2.01 and
26.4mg for natural GABA) and seem to require a long-term
use (1–8 weeks) to improve early sleep measures only. Having
said that, doses ranging between 100 and 300mg seems to be
efficacious in reducing sleep latency with prolonged use of 1–4
weeks. Again, it is important to note that all sleep studies which
reported improved objective sleep measures utilized biosynthetic
forms of GABA. Future research is required to understand (i) the
minimum and optimum natural and biosynthetic GABA doses
required to affect different stages of sleep, and (ii) whether lower
doses might be more efficacious for peripheral markers of sleep.
Limitations
The current review was subject to several limitations. Firstly,
the quality of many of the reviewed studies was questionable
due to potential conflicts of interest, low participant numbers,
and unequal control and intervention groups. Secondly, not all
studies have assessed the same stress and/or sleep parameters
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or employed the same design, hence no quantitative meta-
analysis could be performed due to heterogeneity of the extracted
data. Thirdly, although PICOS (patient-intervention-control-
outcome-study design) was used to extract data, there was only
one data extractor and no validated tool has been used. Finally,
due to the limited number of heterogenous studies in this
area, the precise dose for efficiency for both stress and sleep
benefits could not be established neither in the current review
nor in the general scientific literature. Hence, the current review
encourages future studies to examine dose-response relationships
between oral natural and biosynthetic GABA consumption and
stress and sleep by using self-report, behavioral, peripheral, and
neurophysiological markers of stress and sleep.
CONCLUSION
This review offers a comprehensive assessment of the current
GABA literature and shows that natural and biosynthetic GABA
intake may have beneficial effects on stress and sleep. However,
due to small sample sizes and heterogeneity of methods used,
further research is warranted to establish dose timing, duration,
and response relationships for both natural and biosynthetic
forms of GABA to reliably elicit acute or chronic stress and
sleep effects.
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